Biophytis announces its 2023 financial results and provides an update on its business activities
2024: The actual start of the study will depend on the conclusion of partnership agreements and Biophytis' financial resources.
- 2024: The actual start of the study will depend on the conclusion of partnership agreements and Biophytis' financial resources.
- Promising preclinical results for BIO101 (20-hydroxyecdysone) in obesity, suggesting beneficial metabolic effects on muscle and fat mass.
- On this basis, Biophytis plans to start a phase 1/2 clinical trial in 2024, depending on its financial resources.
- There is therefore significant doubt about the Company's ability to continue its business activities.